Hib causes an estimated 10 000 meningitis cases annually in the United States, primarily in children 2 mo to 5 y old (1) (2) (3) (4) . The mortality rate due to Hib meningitis ranges from 5 to lo%, with about 40% of the survivors developing some degree of permanent neurologic impairment. Other invasive infections involve epiglottitis, septicemia, osteomyelitis, septic arthritis, otitis media, pneumonia, and pericarditis, bringing the total number of Hib disease cases to an estimated 30 000 annually. Approximately half of the disease cases occur during the first year of life. Antibody to the Hib capsular polysaccharide (PRP) is protective (5) (6) (7) . A vaccine-induced antibody level of 1.0 pg anti-PRP/mL has been correlated with long-term protection (8) . Children less than 18-24 mo old do not respond to T-independent antigens such as PRP unless the antigen is conjugated to a T-dependent camer protein. New vaccines exist consisting of PRP conjugated to a camer protein(s), whereby the anti-PRP response is converted to T-dependency. Our report compares the immunogenicity of two Hib conjugate vaccines in an infant rhesus monkey model that to date has been predictive of the immunogenicity of one of the conjugates in human infants (9) .
MATERIALS AND METHODS
Monkeys. Groups of three rhesus monkeys (Macaca mulata), 2-3 mo old of both sexes, were immunized intramuscularly with 0.25-mL doses of vaccine or saline placebo into the flank of each leg (0.5 mL total volume). The small number of animals in each group was dictated by limited availability of the animals. Unless noted otherwise, vaccination was given on d 0, 28, and 56. Infants were housed individually with their mothers at the New Iberia Research Center, Southwestern Louisiana University, New Iberia, Louisiana.
Vaccines. Hib polysaccharide-meningococcal OMPC conjugate vaccine (PedvaxHIB, Merck Sharp and Dohme, West Point, PA) contains PRP covalently coupled to an OMPC from Neisseria meningitidis serogroup B by a thioether linkage (10) . Hib oligosaccharide-CRM19, conjugate vaccine (HibTITER, Praxis Biologics, Rochester, NY) contains Hib oligosaccharides coupled by reductive amination to a carrier protein (CRM197) that is a nontoxic mutant of diphtheria toxin (1 1). These two vaccines are referred to herein as PRP-OMPC and HbOC, respectively.
PRP-OMPC conjugate vaccine (lot Rx42593) contains 15 pg of PRP and 177 pg of OMPC adsorbed to 0.225 mg aluminum hydroxide in 0.5 mL. In a separate study, a second vaccine (lot 1080) adsorbed to aluminum hydroxide was tested at lower doses of PRP: 1 .O, 0.2, and 0.04 pg containing 16.9, 3.4, and 0.7 pg of OMPC, respectively, to demonstrate its immunogenicity range. HbOC (lot M620K) contains 10 pg of PRP and 25 pg of CRM197 protein/0.5 mL. HbOC was administered as a 0.25-mL dose in one leg and 0.25 mL of physiologic saline in the other. The resulting 5-pg oligosaccharide dose of HbOC per monkey was selected to limit the volume/leg to 0.25 mL based on humane considerations, and because serologic data from humans has shown that even 2-pg doses of HbOC are immunogenic (12) . Serology. Blood samples were taken on d 0, 28,42, 56, and 84 unless noted otherwise. Antibody responses to PRP were measured in a RIA procedure (9) using extrinsically labeled IZSI-PRP (from Hib strain Ross) and quantitated using an FDA standard serum (Office of Biologics Research and Review, 1983) . This Hib assay is very similar to that used by most laboratories and, although there are exceptions, such RIA data are comparable to results from the Finnish laboratories (13) . In our study, responders were considered those infant rhesus monkeys that achieved anti-PRP antibody concentrations 2 1.0 pg/mL. Sera were submitted to Advanced Allergy Management Laboratory for anti-D and anti-T determinations using ELISA methods where D or T are noncovalently bound to the polyvinyl surface of microtiter plates (14) . Alkaline phosphatase conjugated antihuman IgG and a p-nitrophenyl phosphate substrate are used. The results are obtained from standard curves based on United States Bureau of Standards reference sera and titers are expressed as the number of antitoxin units/mL. 
RESULTS
None of the infant rhesus monkeys injected with HbOC alone or HbOC/T responded with anti-PRP antibody concentrations of 2 1.0 pg/mL after any of the three doses (Table 1) . However, after the second dose of HbOC/DT, two of three monkeys did respond with 21.0 pg anti-PRP/mL and exhibited a booster response after the third dose. The third monkey did not respond after three injections. Of the two responders, one monkey in the HbOC/DT group responded with an anti-PRP titer of 0.9 pg/ mL after a single injection, which rose to 37.0 pg/mL after the second injection and 65.5 pg/mL after the third injection. The second monkey had a titer of 7.1 pg anti-PRP/mL after the second injection and 15.1 pg/mL after the third injection.
PRP-OMPC was immunogenic in doses ranging from 15 pg to as low as 0.04 pg, with eight of 12 monkeys developing titers 2 1.0 pg/mL after the first dose and 1 1 of 12 responding after the second dose (Tables 1 and 2 ). The HbOC/DT-vaccinated monkey that did not respond with anti-PRP after three injections did respond to a 1.0-pg dose of PRP-OMPC administered on d 96; the prevaccination titer on d 96 was 20.2 pg anti-PRP/mL, whereas the titer was 13.1 pg anti-PRP/mL 32 d later.
All infant rhesus monkeys receiving DT or T responded with protective levels (1 5) of anti-D (20.0 1 AU/mL) and anti-T (20.1 AU/mL) toxoids after two injections ( Table 3 ). The HbOC/DT nonresponder monkey did respond with a protective level of anti-D after two doses (2.2 AU/mL); the other two monkeys responded with protective levels of anti-D after one, two, and three injections (23.2 AU/mL). Increased antibody responses were observed after each D injection. However, no anti-D response (<0.01 AU/mL) was detected in any ofthe three monkeys vaccinated with HbOC alone at a dose that contains 12.5 pg of the nontoxic mutant diphtheria toxin, CRM197 protein.
DISCUSSION
After three doses of HbOC alone, infant rhesus monkeys do not show detectable anti-D or anti-PRP antibody responses. However, animals given concurrent administration of D at a separate site do respond to both antigens. These findings suggest a lack of immunogenicity of the dose of CRM1q7 protein given in this conjugate vaccine in inducing a T-dependent anti-PRP response in these immunologically naive infant rhesus monkeys. These data for anti-D are consistent with previous observations that the immunogenicity of CRMIg7 protein and D are equivalent only if CRMI9, is stabilized by formalin treatment (as per D) (16) , whereas CRM197 protein is not treated with formalin in the course of the process for preparing HbOC. Human infants normally receive twice the dose of HbOC vaccine used in our study of infant monkeys, but doses of less than half that used in our study have been reported to be immunogenic (I 2). The optimal dose of HbOC in infant rhesus monkeys is not known. Nevertheless, our data suggest that an immunologically naive host, such as a human infant, may require concurrent administration of D to elicit an effective anti-PRP response to HbOC.
Of the more than 150 infant rhesus monkeys vaccinated with PRP-OMPC in all previous experiments in this laboratory, all have responded with anti-PRP titers 2 1.0 pg/mL after two doses of vaccine (20.2 pg of polysaccharide per dose) (Vella PP, Ellis RW, unpublished data). These data indicate that all of the infant monkeys tested to date have been able to respond to an Hib conjugate such as PRP-OMPC in the absence of additional camer priming. OMPC has been shown to induce camer priming (17) . The serum anti-D and anti-T antibody concentrations measured in children (1-4 y old) suggest that some do not receive the full complement of DTP immunizations or are not immunized a1 all (18) . Even in those children receiving three doses of DTP, 10% were reported not to have developed protective levels of anti-D (18) . These results suggest that it might be useful for a conjugate vaccine to be independently immunogenic, i.e. not be dependent on the immunogenicity of another vaccine to enable antibody formation. The infant monkey model appears to be predictive of the iimmunogenicity of human infants to PRP-OMPC (9) , and the immunogenicity profiles are the same in that good primary and booster responses are observed with PRP-OMPC (19) . Earlier conjugate studies with a PRP/OMPC conjugate prepared by different chemical means showed that this conjugate was poorly immunogenic in human infants less than 16 mo of age (20) . Subsequently, this conjugate was tested in infant rhesus monkeys and found to be nonimmunogenic after three doses (Vella PP, Ellis RW, unpublished data). On the other hand, the HbOC + DT group does not give a significant primary anti-PRP response after one dose but does induce good responses after the second dose with a boost in anti-PRP levels after the third dose, which is qualitatively equivalent to the profile of HbOC in human infants who do receive DTP concomitantly (21) .
A previous study indicated that placentally transferred antibodies to diphtheria toxin of sufficient titer causes a reduced active immunization antibody response in human infants (22) . This observation may explain why some human infants respond poorly or not at all to D during routine DTP immunizations.
Schneerson et al. (23) tested 5 and 50 pg of PRP-T [which is immunogenic in human infants (24) ] + pneumococcal 6A-T conjugates with and without concurrent administration of T (5 Lf units, at a separate site) in infant rhesus monkeys. Immunogenicity was relatively poor at both doses without concurrent administration of T. Although a T priming effect was observed with 5 pg of PRP-T, there was no further increase in antibody in the 50-pg PRP-T group. The maximal anti-PRP titer observed after three doses of 5 or 50 pg and concurrent T was low (5 1.6 1 pg anti-PRP/mL). In summary, our data indicate that PRP-OMPC independently induces in immunologically naive infant rhesus monkeys serum anti-PRP levels that are above the level thought to be protective (21.0 pg/mL) in humans, whereas HbOC alone is not immunogenic after three doses. However, HbOC is immunogenic only when administered concurrently with DT at a separate site. Inasmuch as some children do not respond to D or do not receive the full complement of DTP vaccines during the first year of life, the role of concurrently administered DTP in the immune response generated in human infants by HbOC would be useful information.
